Browse by author
Lookup NU author(s): Dr Simon Hill
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Context: Synthetic cannabinoids (SCs) such as Spice, K2, etc. are widely available via the internet despite increasing legal restrictions. Currently, the prevalence of use is typically low in the general community (<1%) although it is higher among students and some niche groups subject to drug testing. Early evidence suggests that adverse outcomes associated with the use of SCs may be more prevalent and severe than those arising from cannabis consumption. Objectives: To identify systematically the scientific reports of adverse events associated with the consumption of SCs in the medical literature and poison centre data. Method: We searched online databases (Medline, PsycInfo, Embase, Google Scholar and Pubmed) and manually searched reference lists up to December 2014. To be eligible for inclusion, data had to be from hospital, emergency department, drug rehabilitation services or poison centre records of adverse events involving SCs and included both self-reported and/or analytically confirmed consumption. Results: From 256 reports, we identified 106 eligible studies including 37 conference abstracts on about 4000 cases involving at least 26 deaths. Major complications include cardiovascular events (myocardial infarction, ischemic stroke and emboli), acute kidney injury (AKI), generalized tonic-clonic seizures, psychiatric presentations (including first episode psychosis, paranoia, self-harm/suicide ideation) and hyperemesis. However, most presentations were not serious, typically involved young males with tachycardia (approximate to 37-77%), agitation (approximate to 16-41%) and nausea (approximate to 13-94%) requiring only symptomatic care with a length of stay of less than 8 hours. Conclusions: SCs most frequently result in tachycardia, agitation and nausea. These symptoms typically resolve with symptomatic care, including intravenous fluids, benzodiazepines and anti-emetics, and may not require inpatient care. Severe adverse events (stroke, seizure, myocardial infarction, rhabdomyolysis, AKI, psychosis and hyperemesis) and associated deaths manifest less commonly. Precise estimates of their incidence are difficult to calculate due to the lack of widely available, rapid laboratory confirmation, the variety of SC compounds and the unknown number of exposed individuals. Long-term consequences of SCs use are currently unknown.
Author(s): Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S
Publication type: Review
Publication status: Published
Journal: Clinical Toxicology
Year: 2016
Volume: 54
Issue: 1
Pages: 1-13
Print publication date: 01/01/2016
Online publication date: 15/11/2015
Acceptance date: 14/10/2015
ISSN (print): 1556-3650
ISSN (electronic): 1556-9519
Publisher: TAYLOR & FRANCIS LTD
URL: http://dx.doi.org/10.3109/15563650.2015.1110590
DOI: 10.3109/15563650.2015.1110590
